Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
Peer Reviewed
See detailAn 11 - Year Overview of the belgian donor and transplant statistics bsed on a consecutive yearly data follow-up and comparing two periods : 1997 to 2005 versus 2006 to 2007
Van Gelder, F.; Delbouille, Marie-Hélène ULg; Vandervennet, M. et al

in Transplantation Proceedings (2009), 41

Background. The Belgian Transplant Coordinators Section is responsible for the yearly data follow-up concerning donor and transplantation statistics in Belgium and presents herein a 10-year overview ... [more ▼]

Background. The Belgian Transplant Coordinators Section is responsible for the yearly data follow-up concerning donor and transplantation statistics in Belgium and presents herein a 10-year overview. Methods. The procurement and transplant statistics were compared between 2 periods: Period 1 (P1, 1997–2005) versus Period 2 (P2, 2006–2007). Results. The kidney and liver waiting lists (P1 vs P2) showed an overall decrease for a period of 2 consecutive years in P2; kidney ( 170 patients; 18%), and liver ( 83 patients; 34%). All other waiting lists (heart, lung, pancreas) remained stable. Mean ED further increased (P1 vs P2); 229 (P1) versus 280 (P2, 22.27%). Non–heart-beating donors were significantly ( 288%) more often procured in P2. Mean donor age was 37.9 17.8 years (P1) versus 46.5 19.9 years (P2), and mean organ yield per donor was 3.48 1.7 (P1) versus 3.38 1.8 (P2). Overall transplant activity per million inhabitants increased 21.1%. Conclusion. For 2 consecutive years, the Belgian statistics showed significantly increased donor activity with an impact on waiting list dynamics and transplantation. The mean organ yield per donor was not influenced despite an increased average age and change in reason for death. [less ▲]

Detailed reference viewed: 18 (0 ULg)
See detailLe 11 septembre : un cadeau pour l’extrême droite !
Jamin, Jérôme ULg

Scientific conference (2005)

Detailed reference viewed: 8 (2 ULg)
Peer Reviewed
See detail11-(4-methylpiperazin-1-yl)-5H-pyrido[4,3-b][1,5]benzodiazepine
Dupont, L.; Liégeois, Jean-François ULg; Rogister, F. et al

in Acta Crystallographica Section C-Crystal Structure Communications (1995), C51

Detailed reference viewed: 48 (4 ULg)
Full Text
Peer Reviewed
See detail11-Deoxycortisol impedes GABAergic neurotransmission and induces drug-resistant status epilepticus in mice
Kaminski, R. M.; Venkatesan, Kumar ULg; Mazzuferi, Manuela ULg et al

in Neuropharmacology (2011), 60(7-8), 1098-1108

Detailed reference viewed: 16 (1 ULg)
Full Text
See detail11. Perspectives - 2. La culture en association de froment et de pois: une opportunité pour réduire l'abondance des pucerons en été
Lopes, T.; Bodson, Bernard ULg; Francis, Frédéric ULg

in Bodson, Bernard; Destain, Jean-Pierre (Eds.) Livre Blanc - Céréales (2013, February 27)

Detailed reference viewed: 14 (2 ULg)
Full Text
See detail11. Perspectives - Impact de la gestion culturale sur la respiration d'un sol agricole
Dufranne, Delphine ULg; Vancutsem, Françoise ULg; Aubinet, Marc ULg et al

in Livre Blanc: Céréales - Gembloux (2011, February 23)

Detailed reference viewed: 41 (12 ULg)
Full Text
Peer Reviewed
See detail(111)Indium-oxine labelling for evaluating the homing process of autologous osteoblasts implanted percutaneously in atrophic nonunion fractures.
Hauzeur, Jean-Philippe; Bernard, Claire ULg; Egrise, Dominique et al

in International Orthopaedics (2013), 37(1), 131-6

PURPOSE: The aim of the study was to control the in vivo localisation of implanted cells in cell-based therapies. Labelling cells with (111)indium-oxine is one of the most interesting methods proposed. We ... [more ▼]

PURPOSE: The aim of the study was to control the in vivo localisation of implanted cells in cell-based therapies. Labelling cells with (111)indium-oxine is one of the most interesting methods proposed. We evaluated this method in the setting of autologous osteoblast implantation in nonunion fractures. METHODS: An in vitro study of osteoblasts was conducted after (111)indium-oxine labelling. Radioactivity retention and viability, proliferation and the ability to produce alkaline phosphatase were evaluated in a seven-day culture. In vivo labelling of implanted osteoblastic cells was conducted during a therapeutic trial of atrophic nonunion fractures, with the leakage outside the nonunion site and local uptake evolution at four, 24 and 48 hour being studied. RESULTS: The mean labelling efficiency for osteoprogenitors was 78.8 +/- 4.6 %. The intracellular retention was 89.4 +/- 2.1 % at three hours and 67.3 +/- 4.7 % at 18 hours. The viability assessed at three hours was 93.7 +/- 0.6 %. After seven days of culture, morphology and alkaline phosphatase staining were similar for both labelled and unlabelled control cells, although the proliferation rate was decreased in the labelled cells. Some local intraosseous leakage was observed in four of 17 cases. All patients showed uptake at the injection site, with four having no other uptake. Four patients showed additional uptake in the bladder, liver and spleen, while 11 patients had additional uptake in the lungs in addition to the bladder, liver and spleen. The activity ratios (injection site/body) were 48 +/- 28 % at four hours, 40 +/- 25 % at 24 hours and 35 +/- 25 % at 48 hours. After correcting for decay, the activity within the injection site was 82 +/- 15 % at 24 hours and 69 +/- 11 % at 48 hours compared with the activity measured at four hours. No relationship was found between uptake and radiological bone repair. CONCLUSIONS: The (111)indium-oxine labelling appears to be a good method for monitoring the behaviour of the osteoblastic cells after their implantation in atrophic nonunion fractures. [less ▲]

Detailed reference viewed: 27 (18 ULg)
Full Text
Peer Reviewed
See detailThe 118-135 Peptide Lot The Human Prion Protein Forms Amyloid Fibrils And Induces Liposome Fusion
Pillot, T.; Lins, Laurence ULg; Goethals, M. et al

in Journal of Molecular Biology (1997), 274(3), 381-93

The prion protein (PrPC) is a glycoprotein of unknown function normally found at the surface of neurons and of glial cells. It is involved in diseases such as bovine spongiform encephalopathy, and ... [more ▼]

The prion protein (PrPC) is a glycoprotein of unknown function normally found at the surface of neurons and of glial cells. It is involved in diseases such as bovine spongiform encephalopathy, and Creutzfeldt-Jakob disease in the human, where PrPC is converted into an altered form (termed PrPSc). PrPSc is highly resistant towards proteolytic degradation and accumulates in the central nervous system of affected individuals. By analogy with the pathological events occuring during the development of Alzheimer's disease, controverses still exist regarding the relationship between amyloidogenesis, prion aggregation and neuronal loss. To unravel the mechanism of PrP neurotoxicity and understand the interaction of PrP with cellular membranes, a series of natural and variant peptides spanning residues 118 to 135 of PrP was synthesized. The potential of these peptides to induce fusion of unilamellar lipid vesicles was investigated. According to computer modeling calculations, the 120 to 133 domain of PrP is predicted to be a tilted lipid-associating peptide, and to insert in a oblique way into a lipid bilayer through its N-terminal end. In addition to amyloidogenic properties exhibited in vitro by these peptides, peptide-induced vesicle fusion was demonstrated by several techniques, including lipid- and core-mixing assays. Elongation of the 120 to 133 peptide towards the N- and C-terminal ends of the PrP sequence showed that the 118 to 135 PrP peptide has maximal fusogenic properties, while the variant peptides had no effect. Due to their high hydrophobicity, all peptides tested were able to interact with liposomes to induce leakage of encapsulated calcein. We demonstrate also that the propensity of the peptides to fold as an alpha-helix increases their fusogenic activity, thus accounting for the maximal fusogenic activity of the most stable helix at residues 118 to 135. These data suggest that, by analogy with the C-terminal domain of the beta-amyloid peptide, the fusogenic properties exhibited by the prion peptides might contribute to the neurotoxicity of these peptides by destabilizing cellular membranes. [less ▲]

Detailed reference viewed: 29 (1 ULg)
Peer Reviewed
See detail11C-alkylation on Al2O3/MF: a useful method for rapid labelling.
Schmitz, F.; Plenevaux, Alain ULg; Del Fiore, G. et al

in Journal of Labelled Compounds & Radiopharmaceuticals (1994), 35

Detailed reference viewed: 10 (0 ULg)
Full Text
See detail11th Corporate Finance Day
Lambert, Marie ULg

Scientific conference (2013, September 19)

Detailed reference viewed: 16 (4 ULg)
Full Text
See detail11th Symposium on Fossil Cnidaria and Porifera, Liège, August 19-29, 2011: Abstracts
Aretz, Markus; Delculee, Sandrine; Denayer, Julien ULg et al

Book published by Kölner Forum für Geologie und Paläontologie (2011)

Detailed reference viewed: 61 (9 ULg)
Full Text
Peer Reviewed
See detailLa 11β-hydroxystéroïde déshydrogénase de type 1 – 1re partie Rôle de l’exposition tissulaire au cortisol dans le risque métabolique lié à l’obésité
Iovino, A.; Scheen, André ULg

in Médecine des Maladies Métaboliques (2009), 3

Abdominal obesity plays a key role in the development of metabolic syndrome. Similarities between metabolic syndrome and Cushing disease suggest that excessive local tissue exposition to glucocorticoids ... [more ▼]

Abdominal obesity plays a key role in the development of metabolic syndrome. Similarities between metabolic syndrome and Cushing disease suggest that excessive local tissue exposition to glucocorticoids, despite normal circulating plasma levels, might contribute to the pathophysiology of metabolic syndrome. To this respect, 11β-hydroxysteroid dehydrogenase type 1 (11HSD1), the enzyme which converts cortisone (inactive) to cortisol (active) in target tissues, raises much interest. Indeed, several studies showed both increased expression and activity of this enzyme in adipose tissues in presence of obesity. Even more striking, experimental data in rodents showed a direct link between increased 11HSD1 activity and the development of metabolic abnormalities. Furthermore, studies in mice KO for 11HSD1 confirmed the potential of inhibiting this enzyme to attenuate metabolic abnormalities related to visceral adiposity. Selective inhibitors of 11HSD1 are currently in development, and preliminary results obtained in rodents appear promising, with significant improvements in glucose and lipid profiles. The development of potent and selective 11HSD1 inhibitors may open new prospects in the treatment of metabolic syndrome or type 2 diabetes associated with abdominal obesity in humans. [less ▲]

Detailed reference viewed: 74 (7 ULg)
Full Text
Peer Reviewed
See detailLa 11β-hydroxystéroïde déshydrogénase de type 1 – 2e partie Inhibition sélective pour traiter les anomalies métaboliques associées à l’obésité
Iovino, A.; Scheen, André ULg

in Médecine des Maladies Métaboliques (2009), 3(6), 595-600

La 11β-hydroxystéroïde déshydrogénase de type 1 (11HSD1), qui convertit la cortisone (inactive) en cortisol (actif) dans les tissus cibles, est surexprimée dans certains tissus en présence d’une obésité ... [more ▼]

La 11β-hydroxystéroïde déshydrogénase de type 1 (11HSD1), qui convertit la cortisone (inactive) en cortisol (actif) dans les tissus cibles, est surexprimée dans certains tissus en présence d’une obésité, surtout abdominale, et pourrait jouer un rôle dans les anomalies métaboliques associées. Des inhibiteurs non sélectifs de la 11HSD1 ont déjà été testés chez l’homme et se sont révélés peu efficaces. Le développement de nouveaux inhibiteurs, plus puissants et plus sélectifs, est en cours. Des résultats préliminaires obtenus avec divers inhibiteurs sont prometteurs, avec une diminution de l’insulinorésistance, une amélioration de la tolérance au glucose ou du contrôle glycémique et une correction de certaines anomalies liées au syndrome métabolique. Si ces résultats se confirment, les inhibiteurs sélectifs de la 11HSD1 pourraient représenter à l’avenir une nouvelle classe pharmacologique d’antidiabétiques oraux. Cet article donne au lecteur un aperçu des différentes étapes de réflexion et d’expérimentations humaines qui ont mené au développement d’inhibiteurs de la 11HSD1 à visée thérapeutique. [less ▲]

Detailed reference viewed: 55 (2 ULg)
Peer Reviewed
See detailA 12 Kb Nucleotide Sequence Containing The Alanine Dehydrogenase Gene At 279 Degrees On The Bacillus Subtilis Chromosome
Oudega, B.; Vandenbol, Micheline ULg; Koningstein, G.

in Microbiology-Uk (1997), 143

Detailed reference viewed: 30 (1 ULg)